CN110151752B - Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines - Google Patents
Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines Download PDFInfo
- Publication number
- CN110151752B CN110151752B CN201910474854.6A CN201910474854A CN110151752B CN 110151752 B CN110151752 B CN 110151752B CN 201910474854 A CN201910474854 A CN 201910474854A CN 110151752 B CN110151752 B CN 110151752B
- Authority
- CN
- China
- Prior art keywords
- streptococcus suis
- composition
- tea polyphenol
- polyphenol composition
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of veterinary medicines, and particularly relates to a tea polyphenol composition and application thereof in preparation of an anti-streptococcus suis medicine. The present invention provides tea polyphenol compositions comprising: the composition comprises epigallocatechin gallate (EGCG), gallocatechin (EGC), epicatechin gallate (ECG), gallocatechin gallate (GCG) and catechin (EC), wherein each component of the composition is a series of natural products, the composition has the effects of inhibiting the growth of streptococcus suis and killing streptococcus suis, the minimum inhibitory concentration of the composition on the streptococcus suis is 1024 mug/ml, and the minimum bactericidal concentration of the composition is 4096 mug/ml, so that the toxic and side effects and the potential safety hazard of food of vaccines, chemicals and antibiotics are overcome, and the composition has wide application prospects and development values in the fields of food processing, medicines and breeding industry.
Description
Technical Field
The invention belongs to the technical field of veterinary medicines, and particularly relates to a tea polyphenol composition and application thereof in preparation of an anti-streptococcus suis medicine.
Background
Streptococcus suis is a zoonotic infectious disease pathogen and can cause meningitis, septicemia, arthritis, endocarditis and pneumonia, resulting in the death of pigs and even humans due to infection. The swine streptococcosis not only causes great economic loss to the pig industry, but also poses great threat to the public health safety of human beings. Streptococcus suis is divided into 33 serotypes according to the specificity of bacterial capsular polysaccharide antigens, and among the serotypes, streptococcus suis type 2 is the most pathogenic and the dominant serotype which is often isolated from pigs who die of illness.
The control of swine streptococcosis is mainly carried out by prevention and treatment with antibiotics. However, in recent years, with the large, unjustified use of antibiotics, resistance to bacterial pathogens has become very severe. Clinical experimental data show that streptococcus suis isolated in different countries and regions has different degrees of drug resistance. In the streptococcus suis isolated by Marie, a french scholarer, almost all strains are sensitive to penicillin G, amoxicillin, ceftiofur, florfenicol, gentamicin, bacitracin zinc, and the most serious drug resistance is doxycycline, macrolides and lincosamides. The Korean scholars Dong tested that 55 strains of Streptococcus suis isolated from domestic pigs were resistant to tetracycline, gentamicin and spectinomycin, which were commonly used in clinical practice. 53 streptococcus suis separated from Shandong diseased pigs by Chinese scholars have high drug resistance to common antibiotics and complex drug resistance conditions, particularly the drug resistance to tetracycline, streptomycin, kanamycin and lincomycin is over 80 percent, the drug resistance of sulfonamides reaches 73 percent, and the drug resistance of beta-lactam drugs also reaches 20 percent. The 32 streptococcus suis separated in Guangxi has very common drug resistance and wide drug resistance spectrum, has drug resistance to amoxicillin, has the drug resistance rate of 100 percent, and has drug resistance to more than 3 antibiotics and multiple drug resistance. Therefore, the search for new antibiotic substitutes and the development of new antibacterial drugs have been urgently needed. The tea polyphenol is a polyphenol compound separated and purified from tea leaves, and has excellent antibacterial activity on nearly one hundred pathogenic bacteria of more than ten species groups in nature.
Disclosure of Invention
The technical problem to be solved by the invention is to overcome the serious drug resistance problem of the existing streptococcus suis, and provide a novel composition capable of resisting the streptococcus suis, namely a tea polyphenol composition, wherein the tea polyphenol composition comprises the following components in parts by weight: epigallocatechin gallate (EGCG), gallocatechin (EGC), epicatechin gallate (ECG), gallocatechin gallate (GCG), catechin (EC).
Another problem of the invention is to provide the application of the tea polyphenol composition in preparing medicines for resisting streptococcus suis. The composition provided by the invention has good bacteriostatic and bactericidal effects on the streptococcus suis and has good application prospects in the aspect of preventing and treating the streptococcus suis.
In order to achieve the purpose, the following technical scheme is adopted:
a tea polyphenol composition comprising: epigallocatechin gallate (EGCG), gallocatechin (EGC), epicatechin gallate (ECG), gallocatechin gallate (GCG) and catechin (EC), wherein the weight ratio of the epigallocatechin gallate (EGCG) to the epicatechin gallate (EC) is (50-70): (10-30): (6-25): (1-18): (0.5 to 5);
the composition comprises the following components in an optimal ratio: EGCG: EGC: ECG: GCG: EC 60.39: 18.18: 14.55: 5.16: 1.72, mass ratio.
The application of the tea polyphenol composition in preparing the medicament for resisting the streptococcus suis comprises the steps of preparing the medicament for treating or preventing the streptococcus suis by using the tea polyphenol composition, and inhibiting the growth of the streptococcus suis in vitro or directly killing the streptococcus suis; or can be prepared into a preparation for the medicines for the diseases infected by the streptococcus suis.
In the above application, preferably, the streptococcus suis is streptococcus suis type 2.
Compared with the prior art, the invention has the following advantages and effects:
the invention provides the tea polyphenol composition for the first time, and the composition can be used for resisting streptococcus suis. The invention proves that the tea polyphenol composition has good antibacterial effect on the streptococcus suis through a plurality of methods, lays a theoretical foundation for developing novel medicines for resisting the streptococcus suis, even provides candidate substances for the discovery of antibiotic substitutes, and has good application prospect in the aspect of preventing and treating the streptococcus suis.
Moreover, tea polyphenols have the following advantages: anticancer, antiaging, antioxidant, radioprotective, antibacterial, and antiviral effects. The tea polyphenols have protective effect on pigment and vitamins in food, so that the food can maintain original color and nutrition level for a long time, can effectively prevent food and edible oil from putrefaction, can eliminate peculiar smell, and lays a safety foundation for the food to be widely applied to the aspect of food storage in animal husbandry. In addition, the tea polyphenol has no toxicity to cells on a cellular level, has the characteristics of strong oxidation resistance, no toxic or side effect, no peculiar smell and the like, can be orally taken, has no stimulation, safety and no toxicity to organisms, has no three-effect, is expected to become a novel bioactive molecule for preventing and treating the streptococcus suis, provides a prerequisite for the research and development of antibacterial drugs of the tea polyphenol to the streptococcus suis, has a good application prospect in the aspect of preventing and treating the streptococcus suis, and provides a theoretical basis for the popularization and application of the tea polyphenol as an antibiotic substitute.
Drawings
FIG. 1 is a dynamic analysis of growth curves of tea polyphenol compositions against growth of Streptococcus suis.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available. The examples of the present invention are illustrated by the type 2 Streptococcus suis in Streptococcus suis, to which other Streptococcus suis compositions of the present invention also have inhibitory and killing effects.
Statistical analysis of the following examples of the invention: all experiments were repeated at least 3 times independently, with results expressed as mean and standard error, using one-way analysis of variance and T-test analysis. All statistical analyses used a P <0.05 as a test standard with significant statistical differences and the analysis software was GraphPad Prism 5.
Example 1:
a tea polyphenol composition is prepared from epigallocatechin gallate (EGCG), gallocatechin (EGC), epicatechin gallate (ECG), gallocatechin gallate (GCG) and catechin (EC) according to a mass ratio of 60.39: 18.18: 14.55: 5.16: 1.72, used in the following examples.
Example 2:
the tea polyphenol composition is used for determining the minimum inhibitory concentration and the minimum bactericidal concentration of streptococcus suis:
1. material
Mueller-Hinton (MH) broth (from BD Co.) was used for drug sensitivity experiments to test the bacteriostatic efficacy of drugs.
2. Test method
Selecting a purified streptococcus suis type 2 SC19 bacterial colony by using a sterile inoculating loop, fully dispersing the bacterial colony in an MH liquid culture medium, and preparing a standard bacterial suspension with the concentration of 0.5 McLeod turbidimetric method;
different concentrations of tea polyphenol composition solution diluted by MH liquid medium were added to sterile 96-well polystyrene plates, 50. mu.l of tea polyphenol composition solution was added to wells 1 to 10, 50. mu.l of MH liquid medium was added to well 11 as a growth control, and 100. mu.l of MH liquid medium was added to well 12 as a negative control.
After 0.5M/M.turbidimetric bacterial suspension was diluted 1: 1000 with MH broth, 50. mu.l of the bacterial suspension was added to wells 1 to 11, incubated at 37 ℃ for 16 to 20 hours, and the presence or absence of bacterial growth was observed to determine the MIC value. And sucking bacterial liquid from each hole, coating the bacterial liquid on an MH plate, and counting 5 colonies less to obtain an MBC value.
3. Results
As can be seen from Table 1, the tea polyphenol composition has an inhibitory effect on the growth of Streptococcus suis when the concentration of the tea polyphenol composition is 1024 μ g/ml, and has a bactericidal effect on Streptococcus suis when the concentration of the tea polyphenol composition is 4096 μ g/ml.
TABLE 1 minimum inhibitory and minimum bactericidal concentration of tea polyphenol composition against Streptococcus suis
Example 3:
inhibition of growth curve of streptococcus suis type 2 by tea polyphenol composition
The SC19 colony of purified Streptococcus suis type 2 was picked up by a sterile inoculating loop, dispersed in MH liquid medium, and a standard bacterial suspension with a concentration of 0.5 McLeod was prepared by McLeod's turbidimetry.
Tea polyphenol composition solutions with different concentrations after diluted by MH liquid culture medium are respectively added into a sterile bacteria bottle, and only MH liquid culture medium without tea polyphenol composition solution is grown as a control.
And (3) equivalently inoculating 0.5 McLeod's turbidimetric standard bacterial suspension into the bacterial bottle, placing the bacterial bottle on a 37-degree shaking table for shake culture, taking bacterial liquid at intervals of two hours, diluting the bacterial liquid in a multiple ratio, coating an MH flat plate, and counting viable bacteria, wherein the result is expressed by CFU/ml.
As can be seen from FIG. 1, when the concentration of the tea polyphenol composition was 512. mu.g/ml (i.e., 0.5MIC value), there was no significant difference in the number of bacteria at each time point compared to the control group without the tea polyphenol composition. When the concentration of the tea polyphenol composition is 1024 mu g/ml (namely 1MIC value), the difference of the bacterial count at each time point is obvious compared with that of a control group without the tea polyphenol composition, and the tea polyphenol composition has an antibacterial effect on the streptococcus suis when the concentration is 1024 mu g/ml. When the concentration of the tea polyphenol composition was 4096. mu.g/ml (i.e. 4MIC value), Streptococcus suis was completely killed by the second hour of the culture.
The results show that the tea polyphenol composition can inhibit the growth of the streptococcus suis type 2 and can kill the streptococcus suis type 2.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (3)
1. Use of a tea polyphenol composition in the manufacture of a medicament for the treatment or prevention of streptococcus suis type 2 infection; the tea polyphenol composition is prepared from the following substances in parts by weight: the weight portion proportion of epigallocatechin gallate (EGCG), Epigallocatechin (EGC), epicatechin gallate (ECG), gallocatechin gallate (GCG) and Epicatechin (EC) is 60.39: 18.18: 14.55: 5.16: 1.72.
2. the use according to claim 1, wherein the tea polyphenol composition is used to inhibit growth of streptococcus suis type 2 in vitro.
3. The use according to claim 1, wherein the tea polyphenol composition is used for killing streptococcus suis type 2 in vitro.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910474854.6A CN110151752B (en) | 2019-06-03 | 2019-06-03 | Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910474854.6A CN110151752B (en) | 2019-06-03 | 2019-06-03 | Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110151752A CN110151752A (en) | 2019-08-23 |
| CN110151752B true CN110151752B (en) | 2021-12-31 |
Family
ID=67630630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910474854.6A Active CN110151752B (en) | 2019-06-03 | 2019-06-03 | Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110151752B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111249264B (en) * | 2020-02-18 | 2023-07-07 | 东北农业大学 | Use of gallic acid in reversing resistance of streptococcus suis to antibiotics |
| CN114288287A (en) * | 2022-01-11 | 2022-04-08 | 湖北省农业科学院畜牧兽医研究所 | Application of theaflavin in preparation of anti-streptococcus suis medicine |
| CN115501214B (en) * | 2022-10-14 | 2023-09-22 | 湖北省农业科学院畜牧兽医研究所 | Composition of pyrogallol and sulfamethoxazole and application thereof in inhibiting streptococcus suis type 2 |
| CN116211879B (en) * | 2023-02-07 | 2024-05-31 | 湖北省农业科学院畜牧兽医研究所 | Sabina alcohol and clindamycin composition and application thereof in bacteria inhibition |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939296A (en) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | Theapolyphenol composition and its preparation |
| WO2008081937A1 (en) * | 2006-12-28 | 2008-07-10 | Microbiotech Inc. | Protein toxin secretion inhibitor |
| JP2010159219A (en) * | 2009-01-07 | 2010-07-22 | Kao Corp | Ai-2 inhibitor |
| CN101874859A (en) * | 2010-07-02 | 2010-11-03 | 好维股份有限公司 | Tea extracting solution and preparation method thereof |
| CN101897693A (en) * | 2009-05-26 | 2010-12-01 | 上海医药工业研究院 | Catechin compounds or application of plant extraction containing same and pharmaceutical composition |
| CN101940574A (en) * | 2010-07-23 | 2011-01-12 | 中国人民解放军第三军医大学 | Application of combination of combined catechin substances with antibacterial drugs |
| CN102443053A (en) * | 2010-10-15 | 2012-05-09 | 华中农业大学 | Application of using streptococcus suis type-2 hy0245 gene encoded proteins as protective antigens |
| CN109010331A (en) * | 2018-07-12 | 2018-12-18 | 广州中农大生物科技有限公司 | Tea polyphenols are preventing and treating the application in blue otopathy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI381845B (en) * | 2009-05-21 | 2013-01-11 | Univ Nat Taiwan | Composition for prevention and treatment of helicobacter pylori infection |
-
2019
- 2019-06-03 CN CN201910474854.6A patent/CN110151752B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939296A (en) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | Theapolyphenol composition and its preparation |
| WO2008081937A1 (en) * | 2006-12-28 | 2008-07-10 | Microbiotech Inc. | Protein toxin secretion inhibitor |
| JP2010159219A (en) * | 2009-01-07 | 2010-07-22 | Kao Corp | Ai-2 inhibitor |
| CN101897693A (en) * | 2009-05-26 | 2010-12-01 | 上海医药工业研究院 | Catechin compounds or application of plant extraction containing same and pharmaceutical composition |
| CN101874859A (en) * | 2010-07-02 | 2010-11-03 | 好维股份有限公司 | Tea extracting solution and preparation method thereof |
| CN101940574A (en) * | 2010-07-23 | 2011-01-12 | 中国人民解放军第三军医大学 | Application of combination of combined catechin substances with antibacterial drugs |
| CN102443053A (en) * | 2010-10-15 | 2012-05-09 | 华中农业大学 | Application of using streptococcus suis type-2 hy0245 gene encoded proteins as protective antigens |
| CN109010331A (en) * | 2018-07-12 | 2018-12-18 | 广州中农大生物科技有限公司 | Tea polyphenols are preventing and treating the application in blue otopathy |
Non-Patent Citations (1)
| Title |
|---|
| 儿茶素类化合物抑菌作用及其作用机制的研究进展;陈书媛等;《食品安全质量检测学报》;20170930;第8卷(第9期);第3317页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110151752A (en) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110123806B (en) | Application of epigallocatechin gallate in preparation of anti-streptococcus suis drugs | |
| CN110151752B (en) | Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines | |
| Castillo et al. | 2 (5H)-Furanone, epigallocatechin gallate, and a citric-based disinfectant disturb quorum-sensing activity and reduce motility and biofilm formation of Campylobacter jejuni | |
| Aoki et al. | Changes in drug resistance of Vibrio anguillarum in cultured ayu, Plecoglossus altivelis Temminck and Schlegel, in Japan | |
| CN113061582B (en) | Phage composition, bacteriostatic agent and application thereof | |
| CN114288287A (en) | Application of theaflavin in preparation of anti-streptococcus suis medicine | |
| KR0165132B1 (en) | Antimicrobial agent for staphylococcus | |
| CN114129547B (en) | Application of carvacrol in improving sensitivity of methicillin-resistant staphylococcus aureus to beta-lactam antibiotics | |
| KR101818859B1 (en) | Pseudomonas azotoformans strain KACC 92125P and composition for comprising the same | |
| CN114288286A (en) | Application of theaflavin in preparation of medicine for resisting avian pathogenic bacteria | |
| CN112336715B (en) | Application of inula britannica extract in preparation of medicine for treating swine pleuropneumonia actinobacillus | |
| CN103039723A (en) | Broiler feed additive and preparation method thereof | |
| CN110946857A (en) | Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive | |
| Feng et al. | Effect of matrine on reducing damage to bovine mammary epithelial cells induced by Staphylococcus aureus alpha-hemolysin | |
| CN106939302B (en) | ETEC bacteriophage, biological disinfectant based on bacteriophage and application method of biological disinfectant | |
| CN111821322A (en) | Poultry micro-ecological oral preparation capable of replacing antibiotics and application thereof | |
| CN113384586B (en) | Application of procyanidine flavonoid traditional Chinese medicine monomer in synergistic effect of ceftiofur sodium in resisting MRSA drug-resistant bacteria | |
| CN115350197A (en) | Application of alisol A-24-acetate in improving sensitivity of MRSA to beta-lactam antibiotics | |
| US20220305070A1 (en) | Flavonoid extract of cyclocarya paliurus leaves and antibacterial drugs and/or antibacterial agents containing thereof | |
| CN114940977A (en) | Salmonella anatipestifer bacteriophage, bacteriophage composition thereof and application of salmonella anatipestifer bacteriophage in prevention and treatment of salmonella anatipestifer infection diseases | |
| CN110859832A (en) | Application of myricetin in preparation of salmonella III type secretion system inhibitor | |
| CN112494483B (en) | Application of dithiolethiones compound in antibacterial aspect | |
| CN109498619B (en) | Use of a compound for the preparation of a medicament for the treatment and/or prophylaxis of bacterial diseases | |
| CN112891334B (en) | Application of caffeic acid derivatives in preparation of medicine for treating gonorrhea | |
| Muahiddah et al. | Effectiveness of Garcinia mangostana Mangosteen Peel Extract in Inhibiting Gram-Negative Bacteria in Lobster (Panulirus homarus) Aquaculture Waters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |